Pure Global
NCT06372613

Association Between LRG and Histologic Remission in Ulcerative Colitis

What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
Showa Inan General Hospital·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ulcerative Colitis in Histologic Remission
Study type
Observational
Sponsor & location
Primary sponsor
Showa Inan General Hospital
Location
Komagane, Japan
Timeline & enrollment
Phase
N/A
Start date
Feb 25, 2024
End date
Dec 31, 2025
Enrollment
100 participants
Primary outcome

Histologic remission of UC

Summary

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict
 histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology
 will be performed when histologic remission is predicted, irrespective of symptoms or serum
 LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.

ICD-10 classifications
Ulcerative colitisUlcerative colitis, unspecifiedOther ulcerative colitisArthropathy in ulcerative colitisUlcerative (chronic) rectosigmoiditis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06372613
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06372613 through Pure Global AI's free database. This phase not specified trial is sponsored by Showa Inan General Hospital and is currently Recruiting. The study focuses on Ulcerative Colitis in Histologic Remission. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.